Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

RNAscope ISH for Visualizing AAV Capsid and Genome Biodistribution in Skeletal and Cardiac Muscle

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

RNAscope ISH for Visualizing AAV Capsid and Genome Biodistribution in Skeletal and Cardiac Muscle

RNAscope ISH for AAV Biodistribution in Muscle Tissue

CELL & GENE | RNA | BIOLOGICS

Frequently Asked Questions (FAQ)

    How does RNAscope ISH differentiate between the AAV capsid, vector DNA, and expressed transgene mRNA?

    A: The assay uses distinct, target-specific oligonucleotide probes. We design one probe set to bind to the AAV vector sequence and a separate, spectrally distinct probe set to bind to the mRNA sequence of the expressed transgene. This dual-probe approach allows for simultaneous visualization and co-localization analysis of vector presence versus functional transgene expression within the same tissue section. Capsid protein is typically visualized via immunohistochemistry (IHC), which can be multiplexed with ISH.

    What is the sensitivity for detecting low-copy AAV DNA in cardiac or skeletal muscle?

    A: RNAscope technology can detect single RNA or DNA molecules per cell. Its proprietary probe design and signal amplification system provide high sensitivity and specificity, enabling reliable detection of low-abundance vector DNA even in dense, autofluorescent tissues like cardiac and skeletal muscle.

    Can this method quantify vector DNA per cell?

    A: While primarily a qualitative and semi-quantitative tool for visualizing spatial distribution, the signal can be quantified. By counting the number of punctate dots per cell, we can estimate the relative abundance of vector DNA or transgene transcripts. This provides a semi-quantitative measure that complements absolute quantification from methods like qPCR or ddPCR.

    How do you control for non-specific probe binding in these tissue types?

    A: Each RNAscope probe set consists of multiple oligonucleotide pairs that must bind adjacently to the target sequence to initiate signal amplification. This design significantly reduces the probability of non-specific signal. We run standard positive and negative controls, including probes for housekeeping genes and probes targeting bacterial sequences (e.g., DapB), to validate assay performance and confirm signal specificity in every study.

RNAscope in situ hybridization (ISH) provides single-molecule, single-cell resolution to visualize adeno-associated virus (AAV) vector DNA biodistribution and corresponding transgene expression directly within cardiac and skeletal muscle tissue. This granular pathology data provides a direct method for confirming tissue tropism, assessing transduction efficiency, and de-risking preclinical programs by providing spatial context that bulk homogenization techniques like qPCR cannot.

Defining AAV Vector Performance in Target Tissues

Confirming that an AAV vector reaches its intended target tissue and successfully expresses its therapeutic payload is a foundational step in any gene therapy program. For therapies targeting muscular dystrophies or cardiomyopathies, this requires precise localization within skeletal and cardiac muscle. Traditional biodistribution studies often rely on quantitative PCR of homogenized tissue, a method that confirms vector presence but obscures cellular-level detail.

To build a robust data package for regulatory submission, it is necessary to visualize vector delivery and payload expression with spatial context. RNAscope ISH technology addresses this by enabling the detection of specific nucleic acid sequences within morphologically intact tissue sections. This allows for the direct assessment of:

  • Vector Biodistribution: Which specific cells within the muscle tissue contain the AAV vector DNA?

  • Transduction Efficiency: Of the cells containing the vector, which are actively transcribing the therapeutic payload into mRNA?

  • Non-Target Tissue Biodistribution: Is the vector or transgene expression present in unintended cell types or tissues?

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

Strategic Serotype Selection for Muscle Tropism

The selection of an AAV serotype is a primary determinant of tissue tropism and transduction efficiency. The scientific literature provides a strong basis for selecting candidates for muscle-directed therapies. For example, studies have shown that novel serotypes such as AAV8 can achieve highly efficient gene transfer into skeletal muscle (PMID: 15517544). For cardiac applications, AAV9 has demonstrated superior global gene transfer throughout the heart muscle when compared to other common serotypes (PMID: 18795839).

Our pathology services use RNAscope ISH to provide visual confirmation of these expected distribution patterns in your specific preclinical model. This analysis validates that your chosen vector construct performs as intended, providing confidence in the mechanism of action before advancing to pivotal GxP studies.

)

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner

Integrated Histology for IND-Enabling Programs

These specialized histology services are performed within our >100,000 sq ft facility, which supports comprehensive preclinical programs from vector design through IND submission. Integrating RNAscope ISH data with traditional safety and toxicology readouts creates a more complete narrative for regulatory review. This approach provides a direct link between vector administration, tissue localization, and biological effect.

By generating clear, visual evidence of on-target activity, these studies strengthen the overall data package. This level of detail supports an accelerated development path, contributing to a typical 18-24 month IND timeline. Franklin Biolabs, which launched as a new brand in 2024, is operated by the same scientific team that has maintained a 100% IND-enabling program success rate since 2019. Rapid Pathology Insights Accelerating Preclinical Readouts.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities